Trials / Terminated
TerminatedNCT04822298
Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects With Non-Small Cell Lung Cancer
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the safety and tolerability of AMG 160 and to evaluate the maximum tolerated dose (MTD) or the recommended phase 2 dose (RP2D).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 160 | AMG 160 administered as an intravenous (IV) infusion |
Timeline
- Start date
- 2021-08-31
- Primary completion
- 2021-12-08
- Completion
- 2022-01-26
- First posted
- 2021-03-30
- Last updated
- 2024-07-05
- Results posted
- 2024-07-05
Locations
4 sites across 3 countries: United States, Australia, Austria
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04822298. Inclusion in this directory is not an endorsement.